The TRANSVAC-DS project further builds on the outstanding success of EC-funded projects:TRANSVAC1 and TRANSVAC2 and proposes the establishment of a truly sustainable European vaccine infrastructure, which will build upon the lessons learned, activities and achievements of the TRANSVAC1/2 projects. <br/>Two infrastructure projects -TRANSVAC1 and TRANSVAC2- have been funded by the European Commission which -through the provision of state-of-the-art scientific-technical vaccine development services, technical training, and innovative vaccine research and development- have provided very significant support to European vaccine researchers and developers. Support has been, and is being provided to the development of human and veterinary prophylactic and therapeutic vaccines. <br/>The twenty-five partners in the TRANSVAC-DS consortium that will contribute to the outcome of the project represent ten EU Member States and Associated Countries and include leading organisations from the European vaccine R&D field.<br/>The main output of TRANSVAC-DS will be a conceptual design report that will describe in detail the maturity of the concept and be the basis for the establishment of a permanent and sustainable vaccine infrastructure of direct relevance to and benefit for Europe and further afield. As part of the design report, a five-year business plan will be delivered together with an implementation plan that will guide the further establishment of a sustainable European vaccine infrastructure.